Awareness of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) is low among Americans who have risks associated with the diseases, according to a survey presented at the NASH Summit in Boston. Many clinical trials are currently underway regarding pharmacologic interventions in an area where diet and lifestyle are failing to curb rising incidence of disease.
